Baxter International is emerging from a turbulent period marked by the Vantive spin-off and significant one-time charges, with revenue stabilizing at 5.3% YoY growth in Q2 2026. The company's focus on debt reduction has improved its leverage ratio to 1.56 D/E,...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has stabilized at 5.3% YoY in Q2 2026, but gross margin has compressed to 34.9% from 38.6% in Q1 2024, reflecting persistent cost pressures.
Multiple bullish theses on Baxter International Inc. highlight its potential as a good stock to buy, supported by value investing perspectives.
Baxter's long-standing history since 1931 and its reputation in medical solutions contribute to its enduring market presence.
The company attracts skilled professionals across various fields, enhancing innovation and operational efficiency.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.56+52.8% vs $0.37 | $3.0B+5.9% vs $2.8B |
Q2 2026 Apr 30, 2026 | $0.36+15.8% vs $0.31 | $2.7B+3.3% vs $2.6B |
Q1 2026 Feb 12, 2026 | $0.44-17.0% vs $0.53 | $3.0B+5.3% vs $2.8B |
Q4 2025 Oct 30, 2025 | $0.69+15.0% vs $0.60 | $2.8B+0.4% vs $2.8B |
Bank of America Corp DE acquired a new position in Baxter International Inc. (NYSE: BAX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,237,950 shares of the medical instruments supplier's stock, valued at approximately $132,993,000. Bank of America Corp DE owned
Baxter International (NYSE: BAX - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Volatility and Risk Baxter International has a beta
Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
On Aug. 31, 2026, Richard Pzena (Trades, Portfolio)'s firm, Pzena Investment Management, significantly increased its stake in Globant SA (GLOB, Financial), acqu
Benchmark BAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Baxter International Inc. (BAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.68 | $12.23B | -13.53 | 5.72% | -8.51% | -14.58% | 2.86% | |
| $183.00 | $50.42B | 31.39 | 8.23% | 4.52% | 3.79% | — | |
| $44.92 | $66.77B | 23.15 | 19.87% | 17.47% | 14.76% | — | |
| $88.78 | $51.12B | 48.51 | 11.55% | 15.43% | 9.66% | — | |
| $3.60 | $14.7M | -0.61 | 814.07% | -795.5% | -162.75% | — | |
| $87.43 | $9.96B | 26.74 | 4.03% | 2.96% | 8.38% | — |
Baxter International Inc. (BAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Baxter International Inc. (BAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 14, 2026·SEC
May 8, 2026·SEC
Get notified when BAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Baxter International Inc. (BAX) stock FAQ — growth, dividends, profitability & financials explained
Baxter International Inc. (BAX) reported $11.47B in revenue for fiscal year 2025. This represents a 111% increase from $5.44B in 1996.
Baxter International Inc. (BAX) grew revenue by 5.7% over the past year. This is steady growth.
Baxter International Inc. (BAX) reported a net loss of $1.06B for fiscal year 2025.
Yes, Baxter International Inc. (BAX) pays a dividend with a yield of 2.86%. This makes it attractive for income-focused investors.
Baxter International Inc. (BAX) has a return on equity (ROE) of -14.6%. Negative ROE indicates the company is unprofitable.
Baxter International Inc. (BAX) generated $678.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
